Idorsia Pharmaceuticals US Inc.
One Radnor Corporate Center
100 Matsonford Road, Suite 101
Radnor
Pennsylvania
19087
United States
Tel: 484-253-3887
Website: http://www.idorsia.us/
Email: erika.stearns@idorsia.com
About Idorsia Pharmaceuticals US Inc.
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas; we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland, the US Commercial Operations & Clinical Development teams are based near Philadelphia, Pennsylvania. Idorsia is committed to meet the changing needs of healthcare professionals, patients and their families. The core of what we do is to bring creative solutions to the market based on our science and data.
Company Ownership: Public
Stock Symbol: IDIA
Stock Exchange: SIX Swiss Exchange
CONNECT
27 articles about Idorsia Pharmaceuticals US Inc.
-
Months after Johnson & Johnson turned its back on the hypertension treatment Tryvio, Idorsia has secured the FDA’s nod for the endothelin receptor blocker.
-
US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
3/20/2024
Idorsia Pharmaceuticals U.S. Inc. announced today that the US Food and Drug Administration (FDA) has approved TRYVIO™ (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs.
-
Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration
2/28/2024
Viatris Inc. and Idorsia Ltd announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.
-
Under the research and development agreement announced Wednesday, Viatris is securing global rights to Idorsia’s late-stage heart and lupus candidates.
-
Idorsia and Viatris enter into a significant global research and development collaboration
2/28/2024
Idorsia Ltd announced that it has entered into agreements for a significant global research and development collaboration with Viatris Inc.
-
Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of Insomnia
10/31/2023
Sosei Group Corporation announces that Idorsia Pharmaceuticals Japan Ltd., a Sosei Group company, has submitted a New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for the approval of daridorexant, a dual orexin receptor antagonist which has been co-developed with Mochida Pharmaceutical Co., Ltd., for the treatment of adult patients with insomnia.
-
Tausif ('Tosh') Butt to Join Idorsia Pharmaceuticals U.S. as President and General Manager
8/31/2023
Idorsia Pharmaceuticals U.S. Inc. announced that Tausif Butt will join the organization as the new President and General Manager on September 5, 2023.
-
Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company
7/20/2023
Sosei Group Corporation announces that it has resolved, at a meeting of the Board of Directors held on 20 July 2023, to acquire from Idorsia Ltd and Idorsia Pharmaceutical Ltd all shares of Idorsia Pharmaceuticals Japan Ltd and Idorsia Pharmaceuticals Korea Co., Ltd .
-
Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS
7/10/2023
Idorsia Ltd (SIX: IDIA) and Idorsia Pharmaceuticals US Inc. today announced that, effective immediately, CVS is covering QUVIVIQ® (daridorexant) CIV on the Performance Drug List (PDL).
-
Idorsia Pharmaceuticals Announces Support for a Clinical Trial being Conducted by the U.S. Department of Defense Evaluating QUVIVIQ (daridorexant) as Potential Therapy for Treatment of Posttraumatic Stress Disorder (PTSD)
5/10/2023
Idorsia Pharmaceuticals US Inc. announced today its support of a clinical study sponsored by the U.S. Department of Defense (DOD) to develop new therapies to treat Posttraumatic Stress Disorder (PTSD).
-
Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension
12/20/2022
Idorsia Ltd announced that it has submitted a New Drug Application to the US Food and Drug Administration seeking approval for aprocitentan, Idorsia’s investigational, novel dual endothelin receptor antagonist, for the treatment of patients with difficult-to-control hypertension.
-
Idorsia announces financial results for the first half 2022 – reaching commercial stage
7/26/2022
Idorsia Ltd announced its financial results for the first half of 2022.
-
Idorsia Announces World Champion Skier, Philanthropist and Entrepreneur Lindsey Vonn as Patient Ambassador for QUVIVIQ™ (daridorexant), a Once Nightly Treatment for Insomnia
7/19/2022
Idorsia Pharmaceuticals, U.S. Inc, today announced its partnership with Lindsey Vonn, world champion skier, philanthropist, entrepreneur and insomnia patient as an ambassador for QUVIVIQ™ (daridorexant) CIV.
-
SLEEP 2022: Idorsia U.S. to present data from Wake Up America survey, revealing the hidden toll of insomnia, along with three other abstracts on the evaluation and treatment of insomnia
6/6/2022
Idorsia Pharmaceuticals, U.S. Inc., announced that results from the Wake Up America survey, conducted by The Alliance for Sleep and sponsored by Idorsia, will be presented at SLEEP 2022, the 36th annual congress hosted by the Associated Professional Sleep Societies.
-
Several biopharma companies are opening the week with positive clinical trial news. Read on for updates from Cytokinetics, Concert Pharmaceuticals, Idorsia and Seagen.
-
Idorsia U.S. Announces First Wave of Patients Prescribed QUVIVIQ (daridorexant) through Partnership with Pharmacy Services Provider
5/13/2022
Following the launch of QUVIVIQ™ CIV on May 2, Idorsia Pharmaceuticals, U.S. Inc. announced that the first wave of patients has been prescribed the product through a pharmacy services provider.
-
Idorsia is no longer continuing research into the use of ACT-539313 to treat binge eating disorders after failing to meet the primary endpoint in its latest trial.
-
Idorsia's new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia
5/2/2022
Idorsia Ltd (SIX: IDIA) & Idorsia Pharmaceuticals, US Inc. today announced that QUVIVIQ™ (daridorexant) CIV 25 mg and 50 mg tablets are now commercially available for adult patients with insomnia, which is characterized by trouble with falling or staying asleep.
-
PIVLAZ (clazosentan) – Idorsia’s first commercial product – now available for patients in Japan
4/20/2022
Idorsia Ltd and Idorsia Pharmaceuticals Japan announced that PIVLAZ™ is now available to physicians in Japan to start treating aSAH patients.
-
Results Announced from Largest U.S. Survey of People with Trouble Sleeping, as well as Doctors, to Better Understand the Hidden Toll of Insomnia
4/5/2022
The Alliance for Sleep today announced eye-opening results from its landmark survey, Wake Up America: The Night & Day Impact of Insomnia, conducted online by The Harris Poll.